Seven Fleet Capital Management LP Invests $2.09 Million in Tyra Biosciences, Inc. $TYRA

Seven Fleet Capital Management LP bought a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 79,560 shares of the company’s stock, valued at approximately $2,092,000. Tyra Biosciences makes up approximately 1.6% of Seven Fleet Capital Management LP’s investment portfolio, making the stock its 8th biggest position. Seven Fleet Capital Management LP owned about 0.15% of Tyra Biosciences at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in TYRA. Commodore Capital LP lifted its holdings in shares of Tyra Biosciences by 8.9% in the 3rd quarter. Commodore Capital LP now owns 3,375,000 shares of the company’s stock worth $47,216,000 after purchasing an additional 275,000 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Tyra Biosciences by 2.1% during the fourth quarter. Janus Henderson Group PLC now owns 2,935,442 shares of the company’s stock worth $77,085,000 after buying an additional 60,638 shares in the last quarter. Farallon Capital Management LLC raised its position in Tyra Biosciences by 80.7% in the 4th quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock valued at $54,337,000 after buying an additional 923,000 shares during the last quarter. Vanguard Group Inc. raised its position in Tyra Biosciences by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,520,185 shares of the company’s stock valued at $21,267,000 after buying an additional 118,492 shares during the last quarter. Finally, 5AM Venture Management LLC raised its position in Tyra Biosciences by 9.6% in the 4th quarter. 5AM Venture Management LLC now owns 1,029,298 shares of the company’s stock valued at $27,060,000 after buying an additional 90,000 shares during the last quarter. Institutional investors and hedge funds own 84.14% of the company’s stock.

Tyra Biosciences Price Performance

Tyra Biosciences stock opened at $28.32 on Friday. The firm has a market capitalization of $1.68 billion, a P/E ratio of -12.99 and a beta of 0.75. Tyra Biosciences, Inc. has a one year low of $8.98 and a one year high of $40.65. The business has a fifty day moving average price of $32.85 and a 200-day moving average price of $31.24.

Tyra Biosciences (NASDAQ:TYRA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.04). Sell-side analysts expect that Tyra Biosciences, Inc. will post -2.66 earnings per share for the current fiscal year.

Insider Buying and Selling at Tyra Biosciences

In related news, Director Gilla Kaplan sold 14,295 shares of the company’s stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $36.97, for a total value of $528,486.15. Following the transaction, the director directly owned 28,231 shares in the company, valued at approximately $1,043,700.07. This represents a 33.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 12.50% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Guggenheim started coverage on shares of Tyra Biosciences in a report on Tuesday, April 14th. They set a “buy” rating and a $54.00 price objective on the stock. Canaccord Genuity Group initiated coverage on shares of Tyra Biosciences in a research report on Monday, April 6th. They set a “buy” rating and a $50.00 price target on the stock. JonesTrading initiated coverage on shares of Tyra Biosciences in a report on Wednesday. They set a “buy” rating and a $56.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tyra Biosciences in a research report on Monday, April 20th. Finally, Bank of America increased their price objective on shares of Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Tyra Biosciences has an average rating of “Moderate Buy” and an average price target of $47.00.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.